Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Current Diagnostic Status of Pheochromocytomaand Future Perspective: A Mini Review



Khatami F1 ; Tavangar SM2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Dept. of Pathology, Dr. Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: Iranian Journal of Pathology Published:2017

Abstract

Pheochromocytomas (PCCs) are rare neuroendocrine tumors. The current diagnostic tools are based on biochemistry and histopathology results, but heterogeneity of diagnostic markers, signs and symptoms of PCCs bring a lot of difficulties for these two current methods. Unfortunately, microscopic understanding of PCCs is not adequate for its confident prognosis and management. There are data linking specific genotypes of PCCs tumors to specific locations, typical biochemical phenotypes or future clinical behaviors. The detection of a germ-line mutation possibly can guide us to an early diagnosis, appropriate treatment, and regular surveillance with better prognosis for patients but also and their family members. Moreover, the latest discoveries in gene sequencing, circulating DNA (ctDNA) and circulating tumor cells (CTCs) will support the exact molecular pathogenesis of PCCs to provide an important basis for future PCCs managements. © 2017, IRANIAN JOURNAL OF PATHOLOGY.
Related Docs
View other Related Docs
1. Genetic and Epigenetic Differences of Benign and Malignant Pheochromocytomas and Paragangliomas (Ppgls), Endocrine Regulations (2018)
2. The Emerging Role of Succinate Dehyrogenase Genes (Sdhx) in Tumorigenesis, International Journal of Hematology-Oncology and Stem Cell Research (2019)
3. Multiple Endocrine Neoplasia Syndromes From Genetic and Epigenetic Perspectives, Biomarker Insights (2018)
4. Multiple Endocrine Neoplasia Syndromes From Genetic and Epigenetic Perspectives, Biomarker Insights (2018)
5. Promoter Methylation of Four Tumor Suppressor Genes in Human Papillary Thyroid Carcinoma, Iranian Journal of Pathology (2019)
6. Genetic and Epigenetic of Medullary Thyroid Cancer, Iranian Biomedical Journal (2018)
7. Liquid Biopsy in Thyroid Cancer: New Insight, International Journal of Hematology-Oncology and Stem Cell Research (2018)
8. Circulating Ctdna Methylation Quantification of Two Dna Methyl Transferases in Papillary Thyroid Carcinoma, Journal of Cellular Biochemistry (2019)
Experts (# of related papers)
View all Related Experts
Seyed Mohammad Tavangar (23)
Bagher Larijani (10)
Other Related Docs
9. Personalized Treatment Options for Thyroid Cancer: Current Perspectives, Pharmacogenomics and Personalized Medicine (2019)
10. Liquid Biopsy As a Minimally Invasive Source of Thyroid Cancer Genetic and Epigenetic Alterations, International Journal of Molecular and Cellular Medicine (2019)
11. Hypermethylated Rassf1 and Slc5a8 Promoters Alongside Brafv600e Mutation As Biomarkers for Papillary Thyroid Carcinoma, Journal of Cellular Physiology (2020)
12. Thyroid Cancer Research at Endocrinology and Metabolism Research Institute (Emri): A Report of Scientific Activities Between 2005 and 2020, Journal of Diabetes and Metabolic Disorders (2021)
13. The Impact of Succinate Dehydrogenase Gene (Sdh) Mutations in Renal Cell Carcinoma (Rcc): A Systematic Review, OncoTargets and Therapy (2019)
14. Oncometabolites As Biomarkers in Thyroid Cancer: A Systematic Review, Cancer Management and Research (2019)
15. Expression of the Pituitary Tumor Transforming Gene (Pttg1) in Pheochromocytoma As a Potential Marker for Distinguishing Benign Versus Malignant Tumors, Acta Medica Iranica (2015)
16. Adrenal Collision Tumor Composed of Pheochromocytoma and Diffuse Large B-Cell Lymphoma: A Case Report, International Journal of Hematology-Oncology and Stem Cell Research (2018)
17. A Review of Driver Genetic Alterations in Thyroid Cancers, Iranian Journal of Pathology (2018)
18. The Presence of Tumor Extrachomosomal Circular Dna (Ecdna) As a Component of Liquid Biopsy in Blood, Medical Hypotheses (2018)
19. Circulating Tumor Dna (Ctdna) in the Era of Personalized Cancer Therapy, Journal of Diabetes and Metabolic Disorders (2018)
20. Does This Patient Have Pheochromocytoma? a Systematic Review of Clinical Signs and Symptoms, Journal of Diabetes and Metabolic Disorders (2016)
21. Does This Patient Have Pheochromocytoma? a Systematic Review of Clinical Signs and Symptoms, Journal of Diabetes and Metabolic Disorders (2016)
22. Oncometabolites: A New Insight for Oncology, Molecular Genetics and Genomic Medicine (2019)
23. Clear Cell Sarcoma: A Case Report and Review of Literature, International Journal of Hematology-Oncology and Stem Cell Research (2018)
24. Circulating Tumor Braf Mutation and Personalized Thyroid Cancer Treatment, Asian Pacific Journal of Cancer Prevention (2017)
25. Role of Gata3 in Tumor Diagnosis: A Review, Pathology Research and Practice (2021)
26. The Role of Methylation Quantification of Circulating Tumor Dna (Ctdna) As a Diagnostic Biomarker of Pheochromocytomas (Pccs) and Paragangliomas (Pgls), Journal of Diabetes and Metabolic Disorders (2024)
27. Meta-Analysis of Promoter Methylation in Eight Tumor-Suppressor Genes and Its Association With the Risk of Thyroid Cancer, PLoS ONE (2017)